R. W. Roge & Company Inc. Takes Position in Agilent Technologies, Inc. (NYSE:A)

R. W. Roge & Company Inc. bought a new position in shares of Agilent Technologies, Inc. (NYSE:A) during the third quarter, according to its most recent filing with the SEC. The fund bought 1,498 shares of the medical research company’s stock, valued at approximately $222,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Crewe Advisors LLC grew its holdings in Agilent Technologies by 114.8% during the second quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 101 shares during the period. Livelsberger Financial Advisory purchased a new stake in Agilent Technologies in the 3rd quarter worth about $28,000. Ridgewood Investments LLC bought a new stake in Agilent Technologies in the 2nd quarter valued at about $29,000. Ashton Thomas Securities LLC purchased a new stake in Agilent Technologies during the third quarter valued at about $31,000. Finally, Fortitude Family Office LLC boosted its position in Agilent Technologies by 68.3% during the third quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company’s stock worth $35,000 after purchasing an additional 95 shares during the period.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on A. TD Cowen upped their price target on shares of Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Barclays raised their price target on Agilent Technologies from $135.00 to $145.00 and gave the stock an “underweight” rating in a report on Tuesday, October 15th. Bank of America boosted their price objective on Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a research note on Thursday, August 22nd. UBS Group raised their target price on Agilent Technologies from $141.00 to $150.00 and gave the stock a “neutral” rating in a research note on Thursday, August 22nd. Finally, Wells Fargo & Company started coverage on Agilent Technologies in a research report on Tuesday, August 27th. They set an “overweight” rating and a $157.00 price target on the stock. One analyst has rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $144.36.

Insider Buying and Selling at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total value of $283,910.00. Following the completion of the transaction, the chief executive officer now directly owns 24,118 shares of the company’s stock, valued at $3,497,110. This represents a 7.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Dominique Grau sold 9,990 shares of Agilent Technologies stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the sale, the senior vice president now directly owns 40,011 shares in the company, valued at approximately $5,801,595. The trade was a 19.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,995 shares of company stock worth $1,739,510.

Agilent Technologies Stock Down 1.0 %

Shares of NYSE A opened at $125.70 on Wednesday. The stock has a market capitalization of $36.12 billion, a P/E ratio of 26.08, a PEG ratio of 5.59 and a beta of 1.07. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.78 and a quick ratio of 1.37. Agilent Technologies, Inc. has a one year low of $112.39 and a one year high of $155.35. The firm’s 50 day simple moving average is $138.26 and its two-hundred day simple moving average is $137.83.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.06. The business had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.56 billion. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The company’s revenue was down 5.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.43 earnings per share. As a group, analysts expect that Agilent Technologies, Inc. will post 5.24 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 23rd. Investors of record on Tuesday, October 1st were issued a dividend of $0.236 per share. The ex-dividend date was Tuesday, October 1st. This represents a $0.94 dividend on an annualized basis and a yield of 0.75%. Agilent Technologies’s dividend payout ratio is currently 19.50%.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.